Ratings
Organisations rated 0–100 on five signals. Commercial and academic organisations are ranked separately.
How these scores are derived
- Publications — combined h-index of the organisation's researchers (Google Scholar) plus its own publications.
- Discovery — geroprotective clinical trials it sponsors (ClinicalTrials.gov, verified by lead sponsor), discovered assets, open datasets/tools, and partnership deals. Only aging-relevant trials count.
- Development — clinical-phase depth of those trials (Phase III > II > I).
- Fundraising — companies: equity raised, IPO, deal value and market capitalisation; academic groups: their people's research grants.
- Education — public communicators, conference presence and organising roles, benchmarks and books.
Each signal is scored 0–100 relative to the strongest organisation in its group, then combined with fixed weights. Every figure links to its source; expand an organisation's profile to see the contributors. Scores summarise observed, sourced activity — not intrinsic quality.
Commercial organisations
| # | Organisation | Publications ? | Discovery ? | Development ? | Fundraising ? | Education ? | Score |
|---|---|---|---|---|---|---|---|
| 1 | Insilico Medicine | 87 | 100 | 81 | 81 | 100 | 90 |
| 2 | Pfizer Inc. | 8 | 80 | 100 | 89 | 30 | 71 |
| 3 | Novartis AG | 8 | 69 | 98 | 91 | 60 | 70 |
| 4 | Novo Nordisk A/S | 0 | 60 | 79 | 89 | 60 | 62 |
| 5 | BioAge Labs | 16 | 66 | 41 | 72 | 25 | 49 |
| 6 | Astellas Pharma Inc. | 0 | 60 | 41 | 100 | 5 | 49 |
| 7 | Life Biosciences | 76 | 46 | 0 | 68 | 30 | 42 |
| 8 | Eli Lilly and Company | 16 | 54 | 0 | 95 | 40 | 42 |
| 9 | Calico Life Sciences | 41 | 56 | 0 | 71 | 10 | 38 |
| 10 | Gero | 95 | 32 | 0 | 62 | 5 | 37 |
| 11 | Altos Labs | 100 | 0 | 0 | 75 | 55 | 36 |
| 12 | Cambrian Bio | 33 | 56 | 0 | 64 | 5 | 35 |
| 13 | Rubedo Life Sciences | 16 | 56 | 0 | 61 | 10 | 33 |
| 14 | Retro Biosciences | 8 | 56 | 0 | 65 | 5 | 32 |
| 15 | NewLimit | 16 | 46 | 0 | 70 | 0 | 30 |